Literature DB >> 27125685

Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γ.

Thirumalai R Ramalingam1, Richard L Gieseck1, Thomas H Acciani1, Kevin M Hart1, Allen W Cheever1, Margaret M Mentink-Kane2, Kevin M Vannella1, Thomas A Wynn1.   

Abstract

Persistent or dysregulated IL-13 responses are key drivers of fibrosis in multiple organ systems, and this identifies this cytokine as an important therapeutic target. Nevertheless, the mechanisms by which IL-13 blockade leads to the amelioration of fibrosis remain unclear. Because IFN-γ exhibits potent anti-fibrotic activity, and IL-4Rα signalling antagonizes IFN-γ effector function, compensatory increases in IFN-γ activity following IL-13/IL-4Rα blockade might contribute to the reduction in fibrosis. To investigate the role of IFN-γ, we developed novel IL-13(-/-) /IFN-γ(-/-) double cytokine-deficient mice and examined disease progression in models of type 2-driven fibrosis. As predicted, we showed that fibrosis in the lung and liver are both highly dependent on IL-13. We also observed increased IFN-γ production and inflammatory activity in the tissues of IL-13-deficient mice. Surprisingly, however, an even greater reduction in fibrosis was observed in IL-13/IFN-γ double deficient mice, most notably in the livers of mice chronically infected with Schistosoma mansoni. The increased protection was associated with marked decreases in Tgfb1, Mmp12, and Timp1 mRNA expression in the tissues; reduced inflammation; and decreased expression of important pro-inflammatory mediators such as TNF-α. Experiments conducted with neutralizing monoclonal antibodies to IL-13 and IFN-γ validated the findings with the genetically deficient mice. Together, these studies demonstrate that the reduction in fibrosis observed when IL-13 signalling is suppressed is not dependent on increased IFN-γ activity. Instead, by reducing compensatory increases in type 1-associated inflammation, therapeutic strategies that block IFN-γ and IL-13 activity simultaneously can confer greater protection from progressive fibrosis than IL-13 blockade alone. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  collagen; fibroblast; fibrosis; hydroxyproline; interferon; interleukin 13; liver; lung; tumour necrosis factor

Mesh:

Substances:

Year:  2016        PMID: 27125685      PMCID: PMC4915976          DOI: 10.1002/path.4733

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  58 in total

1.  Allergic host defences.

Authors:  Noah W Palm; Rachel K Rosenstein; Ruslan Medzhitov
Journal:  Nature       Date:  2012-04-25       Impact factor: 49.962

Review 2.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

Review 3.  Acquisition of lymphokine-producing phenotype by CD4+ T cells.

Authors:  R A Seder; W E Paul
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

4.  Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene.

Authors:  A J Dessein; D Hillaire; N E Elwali; S Marquet; Q Mohamed-Ali; A Mirghani; S Henri; A A Abdelhameed; O K Saeed; M M Magzoub; L Abel
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

5.  Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis.

Authors:  N W Lukacs; C Hogaboam; S W Chensue; K Blease; S L Kunkel
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

6.  Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent.

Authors:  P G Fallon; E J Richardson; G J McKenzie; A N McKenzie
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

7.  IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis.

Authors:  K F Hoffmann; A W Cheever; T A Wynn
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

8.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Authors:  Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen
Journal:  Thorax       Date:  2015-05-22       Impact factor: 9.139

9.  TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

Authors:  Liang Zhou; Jared E Lopes; Mark M W Chong; Ivaylo I Ivanov; Roy Min; Gabriel D Victora; Yuelei Shen; Jianguang Du; Yuri P Rubtsov; Alexander Y Rudensky; Steven F Ziegler; Dan R Littman
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

10.  Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response.

Authors:  Monica G Chiaramonte; Margaret Mentink-Kane; Bruce A Jacobson; Allen W Cheever; Matthew J Whitters; Mary E P Goad; Anthony Wong; Mary Collins; Debra D Donaldson; Michael J Grusby; Thomas A Wynn
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  22 in total

1.  Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.

Authors:  Deborah E Citrin; Pataje G S Prasanna; Amanda J Walker; Michael L Freeman; Iris Eke; Mary Helen Barcellos-Hoff; Molykutty J Arankalayil; Eric P Cohen; Ruth C Wilkins; Mansoor M Ahmed; Mitchell S Anscher; Benjamin Movsas; Jeffrey C Buchsbaum; Marc S Mendonca; Thomas A Wynn; C Norman Coleman
Journal:  Radiat Res       Date:  2017-05-10       Impact factor: 2.841

Review 2.  Fibrosis: from mechanisms to medicines.

Authors:  Neil C Henderson; Florian Rieder; Thomas A Wynn
Journal:  Nature       Date:  2020-11-25       Impact factor: 49.962

3.  The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis.

Authors:  Geou-Yarh Liou; Ligia Bastea; Alicia Fleming; Heike Döppler; Brandy H Edenfield; David W Dawson; Lizhi Zhang; Nabeel Bardeesy; Peter Storz
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

Review 4.  Mechanisms of Normal Tissue Injury From Irradiation.

Authors:  Deborah E Citrin; James B Mitchell
Journal:  Semin Radiat Oncol       Date:  2017-10       Impact factor: 5.934

5.  Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis.

Authors:  Virender Kumar; Vinod Kumar; Jiangtao Luo; Ram I Mahato
Journal:  Mol Ther       Date:  2018-09-01       Impact factor: 11.454

Review 6.  Type 2 immunity in tissue repair and fibrosis.

Authors:  Richard L Gieseck; Mark S Wilson; Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2017-08-30       Impact factor: 53.106

Review 7.  The Role of Cytokines in the Fibrotic Responses in Crohn's Disease.

Authors:  Renata Curciarello; Guillermo H Docena; Thomas T MacDonald
Journal:  Front Med (Lausanne)       Date:  2017-08-07

8.  Neutralization of IL-15 abrogates experimental immune-mediated cholangitis in diet-induced obese mice.

Authors:  José L Reyes; Danielle T Vannan; Tina Vo; Aliya Gulamhusein; Paul L Beck; Raylene A Reimer; Bertus Eksteen
Journal:  Sci Rep       Date:  2018-02-15       Impact factor: 4.379

Review 9.  Macrophages, Wound Healing, and Fibrosis: Recent Insights.

Authors:  Kate S Smigiel; William C Parks
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

Review 10.  Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.

Authors:  Martin Braddock; Nicola A Hanania; Amir Sharafkhaneh; Gene Colice; Mats Carlsson
Journal:  Drug Saf       Date:  2018-05       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.